Immunogenicity of two dosages of inactivated, split-virion influenza vaccine given by an alternate route in the elderly.

Trial Profile

Immunogenicity of two dosages of inactivated, split-virion influenza vaccine given by an alternate route in the elderly.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Sep 2008 Primary endpoint results published in The Journal of Infectious Diseases in September 2008
    • 01 Sep 2008 Primary endpoint 'Geometric mean antibody titre' has been met.
    • 02 Apr 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top